ClinicalTrialsFinder

Renal Pelvic Carcinoma Clinical Trials in Tianjin, Outside U.S.

1 recruitingTianjin, Outside U.S., China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

TislelizumabPD-1 InhibitorKidney-sparing+2 more
Tianjin Medical University Second Hospital35 enrolled1 locationNCT07233252